MA04.05 Outcomes in NSCLC Patients Treated With First-Line Pembrolizumab and a PD-L1 TPS of 50-74% vs 75-100% or 50-89% vs 90-100%
Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.343
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2018
Authors
Publisher
Elsevier BV